Skip to content
Screener

Maravai LifeSciences Holdings, Inc. MRVI TriLink — Number of reporting units

Similar metrics at other companies

AT&T logo
TCommunications — Number of reporting units
0.80.0%
Eaton Corporation logo
ETNAerospace — Number of reporting units
2+300%
CBIZ logo
CBZFinancial Services — Number of reporting units
3
CBIZ logo
CBZNational Practices — Number of reporting units
1
Wabtec logo
WABFreight Segment — Number of reporting units
0.50.0%
Enpro logo
NPOSealing Technologies — Number of reporting units
0.80.0%

Other financials

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
Operating cash flow$4.0M+139%
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation

See full
Market cap$918.96M+210%
Enterprise value$1.03B+158%
P/S4.4×+3.1×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NumberOfReportingUnits.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:06 PM EST
Fiscal year
FY2025
Accession
0001823239-26-000011

In connection with preparing its financial statements for the first quarter of 2025, the Company performed a qualitative goodwill impairment analysis on each of its four reporting units (TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies) and concluded that it was more likely than not that the fair value of goodwill exceeded its carrying value for three of the reporting units and no further testing was required. As a result, no impairment was recorded for these three reporting units. The Company performed a quantitative impairment test on the TriLink BioTechnologies reporting unit in response to impairment indicators identified during the first quarter of 2025. The indicators of impairment primarily related to the Company’s long-term forecast which reflected lower projected near term revenues due to lower demand in research and discovery products within the TriLink BioTechnologies reporting unit and slower than expected transition to new mRNA clinical trials as customers prioritize existing programs and more conservatively invest in new programs as the result of macroeconomic pressures. The Company performed the impairment test using a combination of the income and the market approach to determine whether the fair value of the TriLink BioTechnologies reporting unit was less than its carrying value. Based on its interim quantitative assessment, the Company concluded that the TriLink BioTechnologies reporting unit had a

Item 8. Financial Statements and Supplementary Data

FAQ

What is Maravai LifeSciences Holdings, Inc.'s trilink — number of reporting units?
Maravai LifeSciences Holdings, Inc. (MRVI) reported trilink — number of reporting units of 2 in Q2 2025.
What does trilink — number of reporting units mean?
Indicates the count of distinct business components within the TriLink segment that are evaluated for financial reporting and impairment testing purposes. This metric helps investors understand the organizational structure and the granularity at which management monitors performance. Changes in this count may reflect internal restructuring or shifts in how the business manages its diverse product lines.

Ask your AI about Maravai LifeSciences Holdings, Inc.'s trilink — number of reporting units.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude